<DOC>
	<DOCNO>NCT01294787</DOCNO>
	<brief_summary>This study assess effect once-daily indacaterol glycopyrronium bromide ( QVA149 ) exercise endurance patient moderate severe Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>Effect QVA149 Exercise Tolerance Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Diagnosis moderate severe stable Chronic Obstructive Pulmonary Disease ( COPD ) stage II stage III accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guidelines ( 2009 ) Qualifying spirometry , Forced Expiratory Volume one second ( FEV1 ) postbronchodilator FEV1/FVC ( Forced Vital capacity ) Smoking history â‰¥ 10 pack year Pregnant woman nurse mother woman childbearing potential use adequate contraception Cardiac abnormality History asthma Contraindications cardiopulmonary exercise test Participation active phase pulmonary rehabilitation program History cancer within past 5 year Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>COPD</keyword>
	<keyword>QVA149</keyword>
	<keyword>tiotropium</keyword>
	<keyword>exercise</keyword>
	<keyword>exercise tolerance</keyword>
	<keyword>combination bronchodilator</keyword>
	<keyword>moderate severe COPD</keyword>
</DOC>